Nonpeptide glycoprotein IIb/IIIa inhibitors .13. Design and synthesis of an orally active pyrazolopiperazinone nonpeptide fibrinogen receptor antagonist.

被引：26

作者：

Askew, BC ^{[1
]}

McIntyre, CJ ^{[1
]}

Hunt, CA ^{[1
]}

Claremon, DA ^{[1
]}

Baldwin, JJ ^{[1
]}

Anderson, PS ^{[1
]}

Gould, RJ ^{[1
]}

Lynch, RJ ^{[1
]}

Chang, CCT ^{[1
]}

Cook, JJ ^{[1
]}

Lynch, JJ ^{[1
]}

Holahan, MA ^{[1
]}

Sitko, GR ^{[1
]}

Stranieri, MT ^{[1
]}

机构：

[1] MERCK RES LABS,DEPT PHARMACOL,W POINT,PA 19486

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 1997年 / 7卷 / 12期

关键词：

D O I：

10.1016/S0960-894X(97)00256-4

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The synthesis and antiplatelet activity of a series of pyrazolopiperazinone nonpeptide fibrinogen receptor antagonists is reported. The sulfonamide analog 6 (L-734,115), significantly inhibited ex vivo platelet aggregation 24 h after oral administration at doses of 1.0 and 2.0 mg/kg to dogs and rhesus monkeys, respectively. (C) 1997 Elsevier Science Ltd.

引用

页码：1531 / 1536

页数：6

共 50 条

[21] Structure transport studies to identify an orally active nonpeptide endothelin receptor antagonist
Smith, PL
Lee, CP
Elliott, JD
Ohlstein, EH
Fong, KL
Eddy, EP
Ellens, H
Dougherty, P
Lago, A
Nambi, P
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1996, 211 : 13 - BTEC
[22] Clinical Pharmacokinetics of Tirofiban, a Nonpeptide Glycoprotein IIb/IIIa Receptor AntagonistComparison with the Monoclonal Antibody Abciximab
Kazunao Kondo
Kazuo Umemura
Clinical Pharmacokinetics, 2002, 41 : 187 - 195
[23] Synthesis and pharmacology of orally active, isoxazoline glycoprotein IIb-IIIa receptor antagonists
Xue, CB
Wityak, J
Sielecki, TM
Cain, GA
Liu, J
Bostrom, LL
DiMeo, SV
Higley, CA
Lalka, GK
Tobin, AE
Frietze, WE
Emmett, G
Mousa, SA
Sze, JY
Thoolen, MJ
Reilly, TM
DeGrado, WF
Olson, RE
Wexler, RR
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1996, 211 : 132 - MEDI
[24] DESIGN AND BIOLOGICAL EVALUATION OF A NOVEL SERIES OF NONPEPTIDE ANTAGONISTS OF PLATELET GLYCOPROTEIN IIB/IIIA MODELED AFTER THE FIBRINOGEN GAMMA-CHAIN
ANDRADEGORDON, P
FALOTICO, R
HAERTLEIN, B
CORCORAN, T
GIARDINO, E
KEANE, P
HOEKSTRA, W
BEAVERS, MP
THROMBOSIS AND HAEMOSTASIS, 1995, 73 (06) : 1313 - 1313
[25] MK-383 (L-700,462), A SELECTIVE NONPEPTIDE PLATELET GLYCOPROTEIN-IIB/IIIA ANTAGONIST, IS ACTIVE IN MAN
PEERLINCK, K
DELEPELEIRE, I
GOLDBERG, M
FARRELL, D
BARRETT, J
HAND, E
PANEBIANCO, D
DECKMYN, H
VERMYLEN, J
ARNOUT, J
CIRCULATION, 1993, 88 (04) : 1512 - 1517
[26] SELECTION OF AN ORALLY-ACTIVE GLYCOPROTEIN-IIB/IIIA RECEPTOR ANTAGONIST FOR CLINICAL-TRIALS
ZABLOCKI, J
NICHOLSON, N
TAITE, B
PANZERKNODLE, S
SALYERS, A
HAAS, N
SZALONY, J
FEIGEN, L
HERIN, M
JACQMIN, P
LESNE, M
BOVY, P
TJOENG, FS
THROMBOSIS AND HAEMOSTASIS, 1993, 69 (06) : 1244 - 1244
[27] Non-peptide glycoprotein IIb/IIIa inhibitors .17. Design and synthesis of orally active, long-acting non-peptide fibrinogen receptor antagonists
Askew, BC
Bednar, RA
Bednar, B
Claremon, DA
Cook, JJ
McIntyre, CJ
Hunt, CA
Gould, RJ
Lynch, RJ
Lynch, JJ
Gaul, SL
Stranieri, MT
Sitko, GR
Holahan, MA
Glass, JD
Hamill, T
Gorham, LM
Prueksaritanont, T
Baldwin, JJ
Hartman, GD
JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (12) : 1779 - 1788
[28] PHARMACOKINETICS AND PHARMACODYNAMICS OF MK-383, A SELECTIVE NONPEPTIDE PLATELET GLYCOPROTEIN-IIB/IIIA RECEPTOR ANTAGONIST, IN HEALTHY-MEN
BARRETT, JS
MURPHY, G
PEERLINCK, K
LEPELEIRE, ID
GOULD, RJ
PANEBIANCO, D
HAND, E
DECKMYN, H
VERMYLEN, J
ARNOUT, J
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 56 (04) : 377 - 388
[29] Population pharmacokinetics and pharmacodynamics of TS-943 for selective nonpeptide platelet glycoprotein IIb/IIIa receptor antagonist in normal healthy subjects
Furuya, A
Kato, N
Jingu, S
Akimoto, M
Higuchi, S
Suwa, T
Ogata, H
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 67 (05) : 489 - 497
[30] LOSARTAN (DUP 753), AN ORALLY ACTIVE NONPEPTIDE ANGIOTENSIN-II RECEPTOR ANTAGONIST
WONG, PC
BARNES, TB
CHIU, AT
CHRIST, DD
DUNCIA, JV
HERBLIN, WF
TIMMERMANS, PBMWM
CARDIOVASCULAR DRUG REVIEWS, 1991, 9 (04): : 317 - 339

← 1 2 3 4 5 →